Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCSK9 vaccine (bivalent)
- Development stage
- Preclinical
- Lead developer
- The University of New Mexico
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The bivalent PCSK9 vaccine is a peptide-based vaccine formulated using virus-like particles (VLPs) to display two distinct epitopes (amino acids 153–163 and 207–223) from the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein[1][6][8]. By eliciting a robust antibody response that targets both epitopes, the vaccine reduces serum PCSK9 levels, increases hepatic LDL receptor (LDL-R) expression, and lowers circulating LDL cholesterol. The vaccine aims to overcome immune tolerance to the self-antigen PCSK9 and function as a long-acting, cost-effective therapy for hypercholesterolemia and atherosclerotic cardiovascular disease. Preclinical studies in mice and nonhuman primates have shown strong immunogenicity, lipid-lowering efficacy, and a favorable safety profile[1][2][6][8].
- Other names
- bivalent PCSK9 vaccinevirus-like particle-based bivalent PCSK9 vaccinebivalent VLP-PCSK9 vaccine
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on PCSK9 vaccine (bivalent).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCSK9 vaccine (bivalent).